Erasca, Inc. (ERAS)
13.61
-0.61
(-4.29%)
USD |
NASDAQ |
Nov 20, 16:00
13.74
+0.13
(+0.96%)
After-Hours: 20:00
Erasca Enterprise Value : 4.166B for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 4.166B |
| November 19, 2026 | 4.380B |
| November 18, 2026 | 4.219B |
| November 17, 2026 | 4.265B |
| November 16, 2026 | 4.692B |
| November 13, 2026 | 4.884B |
| November 12, 2026 | 4.926B |
| November 11, 2026 | 5.284B |
| November 10, 2026 | 4.821B |
| November 09, 2026 | 4.867B |
| November 06, 2026 | 4.447B |
| November 05, 2026 | 4.047B |
| November 04, 2026 | 4.622B |
| November 03, 2026 | 4.527B |
| November 02, 2026 | 4.321B |
| October 30, 2026 | 4.426B |
| October 29, 2026 | 4.646B |
| October 28, 2026 | 4.695B |
| October 27, 2026 | 4.730B |
| October 26, 2026 | 4.650B |
| October 23, 2026 | 4.440B |
| October 22, 2026 | 4.317B |
| October 21, 2026 | 4.475B |
| October 20, 2026 | 4.520B |
| October 19, 2026 | 4.170B |
| Date | Value |
|---|---|
| October 16, 2026 | 4.089B |
| October 15, 2026 | 4.608B |
| October 14, 2026 | 4.548B |
| October 13, 2026 | 4.576B |
| October 12, 2026 | 4.814B |
| October 09, 2026 | 5.014B |
| October 08, 2026 | 4.814B |
| October 07, 2026 | 4.345B |
| October 06, 2026 | 4.408B |
| October 05, 2026 | 4.555B |
| October 02, 2026 | 4.562B |
| October 01, 2026 | 4.506B |
| September 30, 2026 | 4.534B |
| September 29, 2026 | 4.217B |
| September 28, 2026 | 4.192B |
| September 25, 2026 | 4.230B |
| September 24, 2026 | 4.314B |
| September 23, 2026 | 4.135B |
| September 22, 2026 | 4.636B |
| September 21, 2026 | 4.477B |
| September 18, 2026 | 4.392B |
| September 17, 2026 | 4.571B |
| September 16, 2026 | 4.577B |
| September 15, 2026 | 4.855B |
| September 14, 2026 | 4.827B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Twist Bioscience Corp. | 6.520B |
| Revolution Medicines, Inc. | 32.42B |
| Immunome, Inc. | 1.333B |
| Tango Therapeutics, Inc. | 2.731B |
| Oncolytics Biotech, Inc. | 44.27M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -51.33M |
| Total Expenses (Quarterly) | 51.33M |
| EPS Diluted (Quarterly) | -0.1491 |
| Earnings Yield | -7.32% |
| Normalized Earnings Yield | -4.782 |